Humacyte (HUMA) Q2 2026 earnings summary

Executive summary

• Achieved transformative progress in Q2 2026, advancing commercial launch of SYMVESS, reporting strong clinical trial results for ATEV, and preparing for regulatory filings in dialysis access and coronary artery bypass grafting.

• Commercial launch of SYMVESS began in Q1 2025 for vascular trauma, with FDA approval granted in December 2024 and first shipments in March 2025.

• Rebuilt commercial team and strategy, appointed key advisors and executives, and implemented workforce reduction of 45 employees in May 2026 to drive adoption and cost savings.

• Expanded global rights for the Distribution Product through an amended agreement with Fresenius Medical Care in April 2026.

• Public offerings in 2026 raised over $57.5M to fund commercialization, regulatory filings, and pipeline development.

Financial highlights

• Q2 2026 commercial sales were $0.4M, up from $0.1M in Q2 2025; six-month sales were $0.9M vs. $0.2M year-over-year.

• Cost of goods sold rose to $1.2M in Q2 2026, mainly due to inventory reserves and unused production capacity.

• Net loss was $36.8M for Q2 2026 and $54.4M for the six months, compared to a net loss of $37.7M and net income of $1.5M in the prior year periods.

• Cash, cash equivalents, and restricted cash totaled $80.3M as of June 30, 2026.

• Net cash provided in H1 2026 was $29.4M, driven by equity sales and reduced operational cash use.

Outlook and guidance

• Plans to file a supplemental BLA for ATEV in dialysis access in H2 2026, targeting a potential launch by end of Q2 2027 if granted priority review.

• Phase IIa study of CTEV in CABG patients to begin in Q3 2026.

• Company expects continued operating losses and negative cash flows as commercialization and development efforts expand.

• Insufficient liquidity to fund operations beyond one year without additional capital or increased product revenue; substantial doubt exists about ability to continue as a going concern.

• Focused on reimbursement and value demonstration for payers, leveraging strong clinical and economic data.